<DOC>
	<DOCNO>NCT02770625</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ISU302 patient Type 1 Gaucher disease .</brief_summary>
	<brief_title>Safety Efficacy ISU302 Patients With Type 1 Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Diagnosis Type 1 GD . Documented glucocerebrosidase deficiency . GDrelated anemia , define hemoglobin level least 1 g/dL low limit normal age gender one follow 3 criterion : At least moderate splenomegaly ( 2 3 cm leave costal margin ) palpation , GDrelated thrombocytopenia , define platelet count &lt; 90 x 109 platelets/L , GDrelated readily palpable enlarge liver . Not receive treatment GD ( investigational product , miglustat , velaglucerase alfa , imiglucerase ) within 12 month prior study entry . Ability comprehend willing sign ICF . Legal guardian ( patient age appropriate ) understood nature procedure , willing comply associate followup evaluation , provide write informed consent assent prior procedure . Female patient childbearing potential must agree use medically acceptable method contraception time study . Male patient must use medically acceptable method birth control throughout participation study require report pregnancy partner . Type 2 3 GD . Splenectomy . Antibody positive ISU302 imiglucerase screen patient experience anaphylactic reaction ISU302 imiglucerase . Treatment nonGDrelated investigational drug medical device within 30 day prior study entry ; use study also permit . Currently receive red blood cell ( RBC ) growth factor ( eg , erythropoietin ) chronic systemic corticosteroid receive treatment within last 6 month . Positive human immunodeficiency virus ( HIV ) hepatitis B C. Exacerbated anemia screening ( due iron , folic acid , vitamin B12 deficiency infectious/immunemediated cause ) . Significant comorbidity ( y ) could affect study data confound study result ( eg , malignancy , primary biliary cirrhosis , autoimmune liver disease ) . Pregnant lactate female patient willing use highly effective barrier medical method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Type I Gaucher</keyword>
	<keyword>ISU302</keyword>
	<keyword>Imiglucerase</keyword>
</DOC>